Literature DB >> 25929804

Endogenous VSIG4 negatively regulates the helper T cell-mediated antibody response.

Keunok Jung1, Su-Kil Seo1, Inhak Choi2.   

Abstract

VSIG4 acts as a co-inhibitory ligand to negatively regulate T cell proliferation and cytokine production, and its expression is restricted to macrophages. We hypothesized that endogenous VSIG4 impairs helper T cell functions and then inhibits the subsequent antibody response. Isotype switching of ovalbumin (OVA)-specific antibody subclasses to IgG1, IgG2a, IgG2b, and IgG3 was enhanced in OVA-immunized VSIG4 knockout (KO) mice. 2,4,6-Trinitrophenyl hapten (TNP) - Keyhole Limpet Hemocyanin (KLH)-primed B cells cocultured with OVA-primed CD4(+) T cells from OVA-immunized VSIG4 KO mice in the presence of TNP-OVA showed enhanced isotype switching to IgG subclasses compared to those cocultured with cells isolated from OVA-immunized wild-type (WT) mice. Furthermore, the levels of CD40L expression, the frequency of memory CD4(+) T cells, and the production of isotype switching-inducing cytokines increased significantly in OVA-primed CD4(+) T cells from VSIG4 KO mice. T cells from OVA-specific T cell receptor (TCR) transgenic mice produced more IFN-γ when cocultured with macrophages from VSIG4 KO mice compared to WT mice. Thus, our results demonstrate that macrophage-associated VSIG4 plays a negative role in helper T cell-dependent isotype switching by inhibiting helper T cell activation and differentiation, and suppressing the isotype switching-inducing cytokine production in antigen-primed CD4(+) helper T cells.
Copyright © 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B cells; CD40L; Co-inhibition; Isotype switching; VSIG4

Mesh:

Substances:

Year:  2015        PMID: 25929804     DOI: 10.1016/j.imlet.2015.04.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

1.  Inhibition of Macrophage Complement Receptor CRIg by TRIM72 Polarizes Innate Immunity of the Lung.

Authors:  Nagaraja Nagre; Xiaofei Cong; César Terrazas; Ian Pepper; John M Schreiber; Hongyun Fu; Joshua M Sill; John W Christman; Abhay R Satoskar; Xiaoli Zhao
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

Review 2.  Complement Receptors in Myeloid Cell Adhesion and Phagocytosis.

Authors:  Michael L Dustin
Journal:  Microbiol Spectr       Date:  2016-11

3.  CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites.

Authors:  Katharine M Irvine; Xuan Banh; Victoria L Gadd; Kyle K Wojcik; Juliana K Ariffin; Sara Jose; Samuel Lukowski; Gregory J Baillie; Matthew J Sweet; Elizabeth E Powell
Journal:  JCI Insight       Date:  2016-06-02

4.  Human Dendritic Cells Express the Complement Receptor Immunoglobulin Which Regulates T Cell Responses.

Authors:  Usma Munawara; Khalida Perveen; Annabelle G Small; Trishni Putty; Alex Quach; Nick N Gorgani; Charles S Hii; Catherine A Abbott; Antonio Ferrante
Journal:  Front Immunol       Date:  2019-12-10       Impact factor: 7.561

5.  A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation.

Authors:  Jie Song; Rui Zhao; Chong Yan; Sushan Luo; Jianying Xi; Peipei Ding; Ling Li; Weiguo Hu; Chongbo Zhao
Journal:  Front Immunol       Date:  2022-01-26       Impact factor: 7.561

6.  Upregulation of VSIG4 in Type 2 Diabetic Kidney Disease.

Authors:  Sang Youb Han; Jung Yeon Ghee; Jin Joo Cha; Young Sun Kang; Dae Young Hur; Han Seong Kim; Dae Ryong Cha
Journal:  Life (Basel)       Date:  2022-07-11

7.  Infections with Plasmodium falciparum during pregnancy affect VAR2CSA DBL-5 domain-specific T cell cytokine responses.

Authors:  Komi Gbédandé; Gilles Cottrell; Bertin Vianou; Samad Ibitokou; Aurax Fernando; Marita Troye-Blomberg; Ali Salanti; Kabirou Moutairou; Achille Massougbodji; Nicaise Tuikue Ndam; Philippe Deloron; Adrian J F Luty; Nadine Fievet
Journal:  Malar J       Date:  2016-09-21       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.